PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Appendicitis

Drugs in development · updated 30 October 2026

Appendicitis: drugs in development

As of 30 October 2026 there are 3 active clinical trials (recruiting or ongoing, phases I–III) on 7 drugs for appendicitis. 0 are experimental, that is not yet approved in the United States.

3Active trials
0Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
CeftriaxoneROCEPHIN, Ceftriaxone And Dextrose In Duplex Container®III1NCT07869095
KetorolacAcuvail®, Sprix®III1NCT06160778
MetronidazoleLikmez Oral Suspension, Nuvessa®III1NCT07869095
MorphineArymo Er®, Morphabond Er®III1NCT06160778
PiperacillinPipracil®III1NCT07869095
TazobactamIII1NCT07869095
CefoxitinCefoxitin And Dextrose In Duplex Container®, Mefoxin In Dextrose 5% In Plastic Container®I1NCT06860802

Sorted by most advanced phase and number of active trials.

All 7 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D001064 “Appendicitis”.

ItalianoFrançaisDeutsch